Polyrizon (NASDAQ:PLRZ) Stock Price Down 4.6% – What’s Next?

Polyrizon Ltd. (NASDAQ:PLRZ) shares traded down 4.6% on Wednesday . The company traded as low as $9.12 and last traded at $9.72. Approximately 33,892 shares changed hands during trading, a decline of 42% from the average session volume of 58,792 shares. The stock had previously closed at $10.19.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PLRZ shares. Wall Street Zen raised Polyrizon from a “sell” rating to a “hold” rating in a research note on Sunday, June 7th. Weiss Ratings downgraded Polyrizon from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Polyrizon presently has a consensus rating of “Sell”.

Polyrizon Trading Up 2.1%

The stock’s 50 day moving average price is $12.54 and its 200 day moving average price is $13.30.

Hedge Funds Weigh In On Polyrizon

An institutional investor recently bought a new stake in Polyrizon stock. Jane Street Group LLC purchased a new stake in Polyrizon Ltd. (NASDAQ:PLRZ) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned about 1.35% of Polyrizon as of its most recent SEC filing.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.